You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Nomethiazoles Harnessing GABA and NO mimetic activity for Alzheimer's therapy

    SBC: sGC Pharma Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) occurs in one out of eight Americans of age 65 and affects 43% of the elderly over 85. Current FDA-approved drugs only provide symptomatic relief of AD. There is a pressing need to discover newdisease-modifying medications. AD is multifactorial in origin and progression. A drug attenuating several underlying factors is a preferred ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Insulin Pathway Agonist for Alzheimer's Disease

    SBC: MEDCHEM PARTNERS LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Even though the association of -amyloid peptide (A ) deposition and Alzheimer's Disease (AD) underpins the major hypothesis for disease progression and possibly causation and several drugs addressing the formation or removal of -amyloid plaques have entered clinical trials, no effective therapy exists to date for AD. This reality calls for new targets th ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): In the United States, around 76,250 new cases of melanoma and 9,180 melanoma-related deaths are predicted for 2012. With the therapeutic options currently available, metastatic melanoma patients face the bleak prospectof at best, 10 month's survival and a one-in-ten chance of surviving for 10 years. Surgery and radiation therapy are the mainstay of treatme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Temperature-Tolerant COLD-PCR enables mutation-enriched targeted re-sequencing

    SBC: TRANSGENOMIC, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Cancers develop from the life-long accumulation of critical somatic mutations due to DNA-damaging agents that lead to cells transforming into tumor-forming cells. These low-level tumor-associated somatic DNA mutations can have profound implications for development of metastasis, prognosis, choice of treatment, follow-up or early cancer detection. Unless they ar ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. High Yield Human Hepatocyte Isolation

    SBC: ORGAN SOLUTIONS, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): End-stage liver disease claims about 30,000 lives in the US. Many patients become too ill to tolerate liver transplantation, and even if transplantation were indicated, there is a severe shortage of viable donor organsand only 28% of the wait-listed patients receive transplants. Development and translational studies with novel alternatives to organ transplanta ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. IMPROVING THE TREATMENT OF CONTAMINATED AQUIFERS BYDEVELOPING DIRECT-PUSH OXIDAN

    SBC: AirLIft Environmental LLC            Topic: NIEHS

    DESCRIPTION: Water quality is one of the biggest issues related to public health in the United States. Few situations incite more public outcry than when a community learns that their drinking water has been tainted. Two of the biggest threats to groundwater quality in the U.S. are contamination from either chlorinated solvents or petroleum. Currently, there are an estimated 20,000 sites in the U ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Urinary Biomarkers of Renal Mitochondrial Dysfunction

    SBC: SCHNELLGEN, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): The long-term goal of this project is to identify and validate biomarkers of mitochondrial dysfunction due to environmental stressors. Diverse acute insults from surgery, trauma, ischemia/reperfusion (I/R) and drug andenvironmental chemical toxicity lead to mitochondrial dysfunction and result in cell injury and death in many organs/tissues (e.g. heart, lung, b ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Topical Therapeutic to Promote Healing of Chronic Wounds

    SBC: Phoenicia Biosciences, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Chronic refractory, or non-healing, wounds or ulcerations of the extremities represent a major medical condition affecting millions of patients. A chronic wound is defined as a wound that does not show signs of significant healing, or progresses, after use of topical/surgical treatment measures for six months. Non-healing wounds affect 6.5 million patients, aff ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis

    SBC: RIPARIAN PHARMACEUTICALS INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis Cardiovascular disease is the leading cause of morbidity and mortality in the United States and is an emerging epidemic world-wide. In particular, atherosclerosis is a life-threatening disease strongly associated with risk factors such as elevated cholesterol levels, high blood pressure and d ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Selective HDAC1/2 inhibitors for hemoglobinopathies

    SBC: ACETYLON PHARMACEUTICALS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The long term goal of this project is a selective Histone Deacetylase 1 and 2 (HDAC1/2) inhibitor for the treatment of patients with the beta-hemoglobinopathies sickle cell anemia and beta- thalassemia. An estimated 400,000 children are born each year with one of these hemoglobin disorders. Few treatments exist to alleviate the symptoms of hemoglobinopathies an ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government